Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice

Diabetologia

Volumn 59, Issue 12, 2016, Pages 2674-2685

  McKillop, Aine M ^a   Moran, Brian M ^a   Abdel Wahab, Yasser H A ^a   Gormley, Noella M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Beta cell regeneration; Diabetes; Fatty acid agonists; G protein coupled receptors; Glucose homeostasis; Insulin secretion; Multiple low dose streptozotocin

Indexed keywords

ANTIDIABETIC AGENT; AS 1269574; CANNABIDIOL DERIVATIVE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; G PROTEIN COUPLED RECEPTOR 55; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2-(2-(4-BROMOPHENYL)-6-METHYLPYRIMIDIN-4-YL)AMINOETHANOL; 4-(3-3,4-P-MENTHADIEN-(1,8)-YL)OLIVETOL; ETHANOLAMINE DERIVATIVE; EXENDIN 9; GPR119 PROTEIN, HUMAN; GPR55 PROTEIN, HUMAN; INCRETIN; PEPTIDE FRAGMENT; PYRIMIDINE DERIVATIVE; RESORCINOL DERIVATIVE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; POLYDIPSIA; PRIORITY JOURNAL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; AGONISTS; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; EATING; GENETICS; KNOCKOUT MOUSE; METABOLISM; PANCREAS ISLET BETA CELL;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; EATING; ETHANOLAMINES; INCRETINS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PYRIMIDINES; RECEPTORS, G-PROTEIN-COUPLED; RESORCINOLS; STREPTOZOCIN;

EID: 84988703626     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4108-z     Document Type: Article

References (35)

1. Rayasam GV, Tulasi VK, Davis JA, Bansal VS (2007) Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin Ther Targets 11:661–671
2. Yonezawa T, Kurata R, Yoshida K, Murayama MA, Cui X, Hasegawa A (2013) Free fatty acids-sensing G protein-coupled receptors in drug targeting and therapeutics. Curr Med Chem 20:3855–3871
3. Moran BM, Flatt PR, McKillop AM (2016) G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis. Acta Diabetol 53:177–188
4. Vangaveti V, Shashidhar V, Jarrod G, Baune BT, Kennedy RL (2010) Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. Ther Adv Endocrinol Metab 1:165–175
5. Godlewski G, Offertaler L, Wagner JA, Kunos G (2009) Receptors for acylethanolamides- GPR55 and GPR119. Prostaglandins Other Lipid Mediat 89:105–111
6. Flock G, Holland D, Seino Y, Drucker DJ (2011) GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 152:374–383
7. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153–165
8. Sandoval DA, DʼAlessio DA (2015) Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 95:513–548
9. Moran BM, Abdel-Wahab YH, Flatt PR, McKillop AM (2014) Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice. Biol Chem 395:453–464
10. Yoshida S, Ohishi T, Matsui T, Shibasaki M (2010) Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem Biophys Res Commun 400:437–441
11. Chepurny OG, Bertinetti D, Diskar M et al (2013) Stimulation of proglucagon gene expression by human GPR119 in enterendocrine L-cell line GLUTag. Mol Endocrinol 27:1267–1282
12. Gao J, Tian L, Weng G et al (2011) Stimulating beta cell replication and improving islet graft function by GPR119 agonists. Transpl Int 24:1124–1134
13. Lauffer LM, Iakoubov R, Brubaker PL (2009) GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cells. Diabetes 58:1058–1066
14. Ansarullah LY, Holstein M, DeRuyter B, Rabinovitch A, Guo Z (2013) Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor. PLoS One 8:e53345
15. Zhang M, Feng Y, Wang J et al (2013) High throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice. PLoS One 8:e63861
16. Kapur A, Zhao P, Sharir H et al (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284:29817–29827
17. Romero-Zerbo SY, Rafacho A, Diaz-Arteaga A et al (2011) A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J Endocrinol 211:177–185
18. Lin XH, Yuece B, Li YY et al (2011) A novel CB receptor GPR55 and its ligands are involved in regulation of gut movements in rodents. Neurogastroenterol Motil 23:862–871
19. Staton PC, Hatcher JP, Walker DJ et al (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139:225–236
20. Whyte LS, Ryberg E, Sims NA et al (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106:16511–16516
21. McKillop AM, Moran BM, Abdel-Wahab YHA, Flatt PR (2013) Evaluation of insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta cells, isolated pancreatic islets and mice. Br J Pharmacol 170:978–990
22. Liu B, Song S, Jones PM, Persaud SJ (2015) GPR55: from orphan to metabolic regulator? Pharmacol Ther 145:35–42
23. Meadows A, Lee JH, Wu CS et al (2016) Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity. Int J Obes (Lond) 40:417–424
24. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160:1577–1579
25. Flatt PR, Bailey CJ (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20:573–577
26. Moran BM, Abdel-Wahab YH, Vasu S, Flatt PR, McKillop AM (2016) GPR39 receptors and actions of trace metals on pancreatic beta cell function and glucose homoeostasis. Acta Diabetol 53:279–293
27. Ohly P, Dohle C, Abel J, Seissler J, Gleichmann H (2000) Zinc sulphate induces metallothionein in pancreatic islets of mice and protects against diabetes induced by multiple low doses of streptozotocin. Diabetologia 43:1020–1030
28. Ning Y, Zhen W, Fu Z et al (2011) Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther 337:50–58
29. Moreno-Navarrete JM, Catalán V, Whyte L et al (2012) The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes 61:281–291
30. Yoshida S, Tanaka H, Oshima H et al (2010) AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun 400:745–751
31. Mieczkowska A, Irwin N, Flatt PR, Chappard D, Mabilleau G (2013) Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone 56:337–342
32. Mabilleau G, Mieczkowska A, Irwin N, Flatt PR, Chappard D (2013) Optimal bone mechanical and material properties require a functional GLP-1 receptor. J Endocrinol 219:59–68
33. Chu ZL, Carroll C, Alfonso J et al (2008) A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149:2038–2047
34. Chepurny OG, Holz GG, Roe MW, Leech CA (2016) GPR119 agonist AS1269574 activates TRPA1 cation channels to stimulate GLP-1 secretion. Mol Endocrinol 30:614–629
35. Garber AJ (2011) Incretin effects on β-cell function, replication, and mass. Diabetes Care 34:S258–S263